Alex Biese

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 gene fusion.

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.

The FDA approved Tevimbra with chemotherapy for adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.

Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

For female patients with glioma, pregnancy after receiving a diagnosis of glioma is associated with worse progression-free survival times.

An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia.

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

From the death of a Netflix actress due to stomach cancer complications to an NFL star sharing his chemo experience, here is this week’s cancer news.

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear-cell renal cell carcinoma.